enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Consensus Price Target of $11.05

Key Points

• Analyst sentiment is neutral: Fourteen analysts give enGene a consensus “Hold” rating, with two sells, eight holds, and four buys. The average 12-month price target is $11.05, well above the stock’s recent price of $1.73.
• ENGN remains a highly speculative biotech stock: Shares trade near their 52-week low of $1.40 versus a high of $12.25, while the company posted a quarterly loss of $0.47 per share, missing estimates of a $0.43 loss.
• Institutional ownership is substantial: Hedge funds and other institutions own 64.16% of enGene, with several investors recently initiating or increasing positions. The clinical-stage company is developing genetic medicines, including EG-70 for bladder cancer.

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has received an average recommendation of "Hold" from the fourteen analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $11.05.

A number of brokerages recently commented on ENGN. HC Wainwright reissued a "buy" rating and set a $4.00 price objective on shares of enGene in a report on Tuesday, September 8th. Wall Street Zen upgraded shares of enGene from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th. Citigroup reaffirmed a "market perform" rating on shares of enGene in a research note on Wednesday, September 9th. Morgan Stanley cut shares of enGene from an "equal weight" rating to an "underweight" rating and set a $3.00 price target for the company. in a research report on Thursday, June 18th. Finally, Citizens Jmp reissued a "market perform" rating on shares of enGene in a research note on Wednesday, September 9th.

Hedge Funds Weigh In On enGene

Hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP acquired a new position in shares of enGene in the 1st quarter valued at $251,000. Sei Investments Co. bought a new position in shares of enGene in the 1st quarter worth $409,000. Renaissance Technologies LLC grew its stake in shares of enGene by 651.1% during the first quarter. Renaissance Technologies LLC now owns 156,100 shares of the company's stock worth $1,063,000 after purchasing an additional 135,318 shares during the period. Elmind Capital LP acquired a new stake in shares of enGene during the fourth quarter worth $1,896,000. Finally, Monashee Investment Management LLC grew its stake in shares of enGene by 8.5% during the first quarter. Monashee Investment Management LLC now owns 320,000 shares of the company's stock worth $2,179,000 after purchasing an additional 25,000 shares during the period. 64.16% of the stock is owned by institutional investors.

enGene News Summary

Here are the key news stories impacting enGene this week:

• Neutral Sentiment: Several articles discuss automotive engines, including a U.S. investigation, the Lexus LFA V10, powerful V8 engines, Toyota’s 2ZZ engine, Volkswagen’s VR engine, five-cylinder engines, and diesel or turbocharged engine operation. These stories are unrelated to enGene’s gene-therapy business. Automotive engine investigation
• Neutral Sentiment: Coverage of jet-engine certification focuses on safety testing such as bird strikes, blade failures, and water-ingestion tests; it has no apparent connection to ENGN. How jet engines are certified
• Neutral Sentiment: An article on 3D-printed rocket engines describes aerospace manufacturing trends, but does not involve enGene, its product candidates, or its financial outlook. 3D-printed rocket engines
• Neutral Sentiment: Given the lack of company-specific news, ENGN’s decline appears more likely related to its broader speculative biotech profile, including recent earnings below analyst expectations and continuing projected losses, rather than any of the linked articles. The stock remains well below its 52-week high.

enGene Price Performance

NASDAQ:ENGN opened at $1.73 on Monday. The stock's fifty day moving average price is $1.85 and its two-hundred day moving average price is $2.98. enGene has a 52-week low of $1.40 and a 52-week high of $12.25. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.21 and a current ratio of 10.21. The company has a market cap of $115.94 million, a price-to-earnings ratio of -1.53 and a beta of -0.29.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.04). On average, analysts anticipate that enGene will post -1.81 EPS for the current year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.